Lamberson Miles, King Roz, Waters Colin T, Jackson Peter, Brooklyn John, Riser Elly, Wolfson Daniel
University of Vermont Larner College of Medicine, Department of Emergency Medicine, Burlington, Vermont University of Vermont.
Larner College of Medicine, Department of Psychiatry, Burlington, Vermont.
Clin Pract Cases Emerg Med. 2025 May;9(2):188-192. doi: 10.5811/cpcem.39968.
The prevalence of high-potency synthetic opioids (HPSO), such as fentanyl and its analogs, presents significant treatment challenges to current strategies for emergency department (ED) initiation of medication for opioid use disorder (MOUD). While most EDs traditionally use buprenorphine for MOUD, its effectiveness can be limited in patients exposed to HPSOs due to risk of precipitated withdrawal or inadequate control of withdrawal symptoms. Methadone, a full agonist, is another MOUD agent that addresses severe withdrawal symptoms and cravings associated with HPSO dependence and will not cause precipitated withdrawal. Traditional methadone protocols often fail to provide sufficient doses to alleviate withdrawal symptoms, but new federal guidelines allow higher initial doses and rapid titration to therapeutic levels.
We report a case of rapid methadone titration in the ED for a patient with a history of high HPSO utilization. The patient received an initial dose of methadone 50 milligrams (mg) orally, followed by titration of additional 10 mg doses hourly to a cumulative dose of 70 mg at discharge. Vital signs, mental status, and Clinical Opiate Withdrawal Scale scores were monitored to guide dosing.
The protocol allowed for safe, individualized care, achieving therapeutic dosing levels that alleviated withdrawal symptoms and enabled the patient to transition to outpatient follow-up treatment. This approach addresses the need for rapid, effective methadone initiation in an era in which high-potency synthetic opioids pose challenges to traditional opioid use disorder treatment.
强效合成阿片类药物(HPSO),如芬太尼及其类似物的流行,给当前急诊科(ED)启动阿片类药物使用障碍(MOUD)药物治疗策略带来了重大挑战。虽然大多数急诊科传统上使用丁丙诺啡治疗MOUD,但由于存在戒断反应或戒断症状控制不足的风险,其在接触HPSO的患者中的有效性可能有限。美沙酮作为一种完全激动剂,是另一种可解决与HPSO依赖相关的严重戒断症状和渴望且不会引起戒断反应的MOUD药物。传统的美沙酮方案往往无法提供足够剂量来缓解戒断症状,但新的联邦指南允许更高的初始剂量并快速滴定至治疗水平。
我们报告了一例在急诊科对有高HPSO使用史的患者进行美沙酮快速滴定的病例。患者口服初始剂量50毫克(mg)美沙酮,随后每小时滴定额外10mg剂量,出院时累积剂量达70mg。监测生命体征、精神状态和临床阿片戒断量表评分以指导给药。
该方案实现了安全、个性化护理,达到了缓解戒断症状并使患者能够过渡到门诊后续治疗的治疗剂量水平。在强效合成阿片类药物对传统阿片类药物使用障碍治疗构成挑战的时代,这种方法满足了快速、有效启动美沙酮治疗的需求。